MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease
Key facts
- Who runs it
- University Hospital, Basel, Switzerland
- Where
- Switzerland and United Kingdom4 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 277 people enrolled
- Started
- 27 Aug 2015
- Ended
- 10 Jun 2024
- Type of study
- Observational, 6 groups
- Treatments tested
- blood sampling for research purpose
- clinical data collection
- Health-related Questionnaires
- Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)
- Record updated
- 25 June 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients with compensated or decompensated chronic liver disease
- Patients with acute- or acute-on-chronic chronic liver failure
- Controls with no liver disease
Who cannot take part
- Evidence of disseminated malignancy
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is to investigate MER receptor tyrosine kinase (MERTK) signalling cascade on monocytes and tissue macrophages in respect to innate immune function of the cells in patients with cirrhosis at different stages of disease (Child A, B, C, acute decompensation, acute-on-chronic liver failure (ACLF)) and in comparison to patients with acute liver failure and to healthy controls.
The 6 groups in the trial
- cirrhosis of the liver, stadium Child A
sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months
Treatment: blood sampling for research purpose, clinical data collection, Health-related Questionnaires, and Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)
- cirrhosis of the liver, stadium Child B
sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months
Treatment: blood sampling for research purpose, clinical data collection, Health-related Questionnaires, and Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)
- cirrhosis of the liver, stadium Child C
sampling of biological material and health related data collection longitudinally in 6-monthly intervals up to 36 months
Treatment: blood sampling for research purpose, clinical data collection, Health-related Questionnaires, and Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)
- cirrhosis of the liver, acutely decompensated
sampling of biological material and health related data collection on days 1 (Baseline), 3, 7, and 14. If acutely decompensated patients re-compensate they will be followed 6-monthly for up to 36 months
Treatment: blood sampling for research purpose, clinical data collection, Health-related Questionnaires, and Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)
- acute liver failure
sampling of biological material and health related data collection on days 1 (Baseline), 3, 7, and 14. If acutely decompensated patients re-compensate they will be followed 6-monthly for up to 36 months
Treatment: blood sampling for research purpose, clinical data collection, Health-related Questionnaires, and Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)
- healthy controls
sampling of biological material and health related data collection on day 1 (Baseline)
Treatment: blood sampling for research purpose, clinical data collection, and Health-related Questionnaires
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 25 June 2024